15.83
1.85 (13.23%)
| Penutupan Terdahulu | 13.98 |
| Buka | 14.17 |
| Jumlah Dagangan | 3,842,092 |
| Purata Dagangan (3B) | 1,058,404 |
| Modal Pasaran | 1,350,275,200 |
| Harga / Jualan (P/S) | 88.07 |
| Harga / Buku (P/B) | 26.40 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 |
| Margin Operasi (TTM) | -1,135.42% |
| EPS Cair (TTM) | -1.71 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 297.04% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -99.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.38 M |
| Pulangan Atas Aset (ROA TTM) | -37.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -203.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Liquidia Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.48% |
| % Dimiliki oleh Institusi | 65.03% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Patient Square Capital Lp | 31 Dec 2024 | 1,860,371 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 37.00 (Scotiabank, 133.73%) | Beli |
| Median | 27.00 (70.56%) | |
| Rendah | 13.00 (Oppenheimer, -17.88%) | Jual |
| Purata | 27.00 (70.56%) | |
| Jumlah | 5 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 15.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 May 2025 | 35.00 (121.10%) | Beli | 15.35 |
| 12 May 2025 | 29.00 (83.20%) | Beli | 15.75 | |
| Needham | 28 May 2025 | 25.00 (57.93%) | Beli | 15.35 |
| 21 May 2025 | 25.00 (57.93%) | Beli | 16.66 | |
| Scotiabank | 28 May 2025 | 37.00 (133.73%) | Beli | 15.35 |
| 05 May 2025 | 36.00 (127.42%) | Beli | 16.12 | |
| Wells Fargo | 28 May 2025 | 23.00 (45.29%) | Beli | 15.35 |
| Oppenheimer | 19 May 2025 | 13.00 (-17.88%) | Jual | 17.03 |
| Raymond James | 09 May 2025 | 29.00 (83.20%) | Beli | 15.26 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |